
Myriad Genetics (MYGN) Stock Forecast & Price Target
Myriad Genetics (MYGN) Analyst Ratings
Bulls say
Myriad Genetics Inc. is expected to experience a solid upward trajectory in its revenue, with projected growth of 6% year-over-year for 2026, primarily driven by a 10% increase in Prenatal testing and mid-single digit growth across other divisions such as Hereditary Cancer Testing and Pharmacogenomics. The company’s strategic launch initiatives in the oncology segment, including the introduction of Precise MRD and MyRisk with RiskScore, are poised to enhance its portfolio and potentially boost market share over the next 12-18 months. Additionally, strong test volume growth across various testing services underscores a favorable outlook for sustained business expansion in the evolving molecular diagnostics landscape.
Bears say
Myriad Genetics Inc. has recently experienced a downgrade to Sector Perform, alongside a reduction in the price target to $6, indicating a decline in investor confidence. This outlook may reflect underlying concerns regarding the company's growth potential and competitive position within the molecular diagnostics market. Additionally, the consistent reiteration of the downgraded stance suggests a persistent evaluation of challenges facing the company's financial performance.
This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.
Myriad Genetics (MYGN) Analyst Forecast & Price Prediction
Start investing in Myriad Genetics (MYGN)
Order type
Buy in
Order amount
Est. shares
0 shares